Core Viewpoint - The company reported a significant decline in revenue and an increase in losses for the fiscal year ending June 30, 2025, primarily due to the impact of new healthcare policies in China [1] Financial Performance - The company recorded revenue of RMB 710 million, a year-on-year decrease of 34.7% [1] - The loss attributable to shareholders was RMB 26 million, compared to a profit of RMB 400,000 in 2024 [1] - Earnings per share were RMB -0.3246, a decline from an adjusted profit of RMB 0.0062 per share in 2024 [1] Market and Operational Challenges - Revenue decline was attributed to the new healthcare policies in China and a decrease in the number of active customers within the national distribution network [1] - The company is actively participating in alliance activities to enhance its industry influence and brand product development [1] Strategic Initiatives - The company is focusing on national strategic initiatives such as "Healthy China," "Beautiful China," "Belt and Road," "Guangdong-Hong Kong-Macao Greater Bay Area," and "Hainan Free Trade Port" to guide its business transformation and upgrade [1] - The company aims to leverage industry experience and focus on technological innovation to explore further business transformation directions [1]
大健康国际(02211.HK)年度收益7.1亿元 同比减少34.7%